Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Orkla on its divestment of Enter Fonder to Pareto
Mandate

Vinge advises Orkla on its divestment of Enter Fonder to Pareto

April 04, 2016

Vinge advises Orkla ASA on the divestment (indirectly) of its shares in Enter Fonder to Pareto AS. The transaction makes Pareto the new majority shareholder of Enter. The transaction is subject to relevant approvals from the Swedish Financial Supervisory Authority (Finansinspektionen).

Vinge’s team consists of partner in charge Peter Sundgren (M&A), partner Emma Stuart-Beck (financial regulatory), partner Odile Fallenius and counsel Maria Schultzberg (tax) and associates Oscar Rydén and Louise Nordkvist (M&A).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025